1. Patients who are participating in other drug clinical trials, 2. Pregnant or lactating women, 3. ALT / AST> 5 ULN, neutrophils <0.5, platelets less than 50, 4. Expected survival is less than 1 week, 5. Patients diagnosed with rheumatic immune related diseases, 6. Take orally anti rejection drugs or immunomodulatory drugs for a long time, 7. Hypersensitive to adalimumab or any excipients, 8. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections

1. Patients who are participating in other drug clinical trials, 2. Pregnant or lactating women, 3. ALT / AST> 5 ULN, neutrophils <0.5, platelets less than 50, 4. Expected survival is less than 1 week, 5. Patients diagnosed with rheumatic immune related diseases, 6. Take orally anti rejection drugs or immunomodulatory drugs for a long time, 7. Hypersensitive to adalimumab or any excipients, 8. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections